These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
587 related articles for article (PubMed ID: 11768880)
1. T-20 small program, CD4 < 50, will enroll November 27 at 3:00 P.M. James JS AIDS Treat News; 2001 Oct; (373):3. PubMed ID: 11768880 [No Abstract] [Full Text] [Related]
2. [HIV-1 fusion inhibitor improves treatment in HIV-1-resistant patients]. Blasko M Dtsch Med Wochenschr; 2003 May; 128(19):1032. PubMed ID: 12774800 [No Abstract] [Full Text] [Related]
3. [Fusion inhibitors. One year therapy with T-20--initial evaluation]. Goebel FD MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046 [No Abstract] [Full Text] [Related]
13. Long path to approval. A look back at the road to Fuzeon. GMHC Treat Issues; 2003 Mar; 17(3):1-5. PubMed ID: 12728856 [No Abstract] [Full Text] [Related]
14. New-Fill on "hold" and open-label for T-20. Berger DS Posit Aware; 2002; 13(1):64-5. PubMed ID: 12216532 [No Abstract] [Full Text] [Related]
15. T-20 being called "miraculous". AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581 [No Abstract] [Full Text] [Related]
18. Fusion inhibitor approved. AIDS Patient Care STDS; 2003 May; 17(5):253. PubMed ID: 12816619 [No Abstract] [Full Text] [Related]
19. Enfuvirtide (Fuzeon) for HIV Infection. Med Lett Drugs Ther; 2003 Jun; 45(1159):49-50. PubMed ID: 12817195 [No Abstract] [Full Text] [Related]
20. New class of medications approved for advance HIV. FDA Consum; 2003; 37(3):5. PubMed ID: 12793380 [No Abstract] [Full Text] [Related] [Next] [New Search]